Cyclic sulfamide compounds and methods of using same

A compound and formyl technology, applied to cyclic sulfonamide compounds and their application fields, can solve problems such as poor side effect tolerance of interferon alpha

Pending Publication Date: 2019-12-27
ASSEMBLY BIOSCI
View PDF20 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Interferon alfa has severe side effects and is poorly tolerated in patients and is o

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Cyclic sulfamide compounds and methods of using same
  • Cyclic sulfamide compounds and methods of using same
  • Cyclic sulfamide compounds and methods of using same

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0379]The compounds described herein can be prepared in a variety of ways based on the teachings contained herein and synthetic procedures known in the art. In the description of the synthetic methods described hereinafter, it is understood that, unless otherwise mentioned, all suggested reaction conditions, including solvent, reaction atmosphere, reaction temperature, duration of experiments and selection of work-up steps, can be chosen as Standard conditions for this reaction. Those skilled in the art of organic synthesis will appreciate that the functionality present in each part of the molecule should be compatible with the proposed reagents and reactions. Substituents which are incompatible with the reaction conditions will be apparent to those skilled in the art and alternatives are thus indicated. Starting materials used in the examples are either commercially available or readily prepared by standard methods from known materials. At least some of the compounds identi...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present disclosure provides, in part, cyclic sulfamide compounds, and pharmaceutical compositions thereof, useful as modulators of Hepatitis B (HBV) core protein, and methods of treating HepatitisB (HBV) infection.

Description

[0001] related application [0002] This application claims U.S. Provisional Application No. 62 / 465986, filed March 2, 2017, U.S. Provisional Application No. 62 / 529,874, filed July 7, 2017, U.S. Provisional Application No. 62 / 549,728, filed August 24, 2017 the priorities and interests of each of which is incorporated by reference in its entirety. Background technique [0003] Hepatitis B (HBV) causes viral hepatitis, which can further lead to chronic liver disease and increase the risk of cirrhosis and liver cancer (hepatocellular carcinoma). Worldwide, about 2 billion people have been infected with HBV, about 360 million people are chronically infected, and HBV infection causes more than 500,000 deaths every year. HBV can be transmitted through bodily fluids: from mother to child, sexually and through blood products. Children born to HBV-positive mothers can also become infected unless vaccinated at birth. [0004] The hepatitis virion consists of a lipid outer membrane co...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C07D417/04C07D417/14A61P31/12A61K31/549
CPCC07D417/04C07D417/14A61P31/12A61K31/549A61P31/20C07D285/16C07D417/10
Inventor W.J.小特纳L.李S.N.海达尔M.G.布赖什R.莱S.弗朗西斯L.D.阿诺德
Owner ASSEMBLY BIOSCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap